Based on a successful phase 3 clinical trial [27], the FDA has approved semaglutide, a glucagon-like peptide-1 (GLP-1), for the treatment of patients with MASH and stage 2 or 3 fibrosis. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.